297 related articles for article (PubMed ID: 19626830)
1. The role of LHRH antagonists in the treatment of prostate cancer.
Crawford ED; Hou AH
Oncology (Williston Park); 2009 Jun; 23(7):626-30. PubMed ID: 19626830
[TBL] [Abstract][Full Text] [Related]
2. Utility of LHRH antagonists for advanced prostate cancer.
Moul JW
Can J Urol; 2014 Apr; 21(2 Supp 1):22-7. PubMed ID: 24775720
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer.
Klotz L
Expert Opin Drug Metab Toxicol; 2015; 11(11):1795-802. PubMed ID: 26513436
[TBL] [Abstract][Full Text] [Related]
4. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer.
Kirby RS; Fitzpatrick JM; Clarke N
BJU Int; 2009 Dec; 104(11):1580-4. PubMed ID: 20053189
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer.
Hatoum HT; Crawford ED; Nielsen SK; Lin SJ; Marshall DC
Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):261-70. PubMed ID: 23570437
[TBL] [Abstract][Full Text] [Related]
6. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
7. Agonists of luteinizing hormone-releasing hormone in prostate cancer.
Rick FG; Block NL; Schally AV
Expert Opin Pharmacother; 2013 Nov; 14(16):2237-47. PubMed ID: 23984804
[TBL] [Abstract][Full Text] [Related]
8. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
Van Poppel H; Klotz L
Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
10. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.
Clinton TN; Woldu SL; Raj GV
Expert Opin Pharmacother; 2017 Jun; 18(8):825-832. PubMed ID: 28480768
[TBL] [Abstract][Full Text] [Related]
11. Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer.
Rick FG; Schally AV
Urol Oncol; 2015 Jun; 33(6):270-4. PubMed ID: 25512159
[TBL] [Abstract][Full Text] [Related]
12. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues.
Weckermann D; Harzmann R
Eur Urol; 2004 Sep; 46(3):279-83; discussion 283-4. PubMed ID: 15306097
[TBL] [Abstract][Full Text] [Related]
13. Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors?
Tolkach Y; Joniau S; Van Poppel H
BJU Int; 2013 Jun; 111(7):1021-30. PubMed ID: 23418666
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy: past, present and future.
Schröder F; Crawford ED; Axcrona K; Payne H; Keane TE
BJU Int; 2012 Jun; 109 Suppl 6():1-12. PubMed ID: 22672120
[TBL] [Abstract][Full Text] [Related]
15. Does Exist a Differential Impact of Degarelix
Sciarra A; Busetto GM; Salciccia S; Del Giudice F; Maggi M; Crocetto F; Ferro M; De Berardinis E; Scarpa RM; Porpiglia F; Carmignani L; Damiano R; Artibani W; Carrieri G
Front Endocrinol (Lausanne); 2021; 12():695170. PubMed ID: 34194398
[TBL] [Abstract][Full Text] [Related]
16. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
17. Degarelix: a new approach for the treatment of prostate cancer.
Persson BE; Kold Olesen T; Jensen JK
Neuroendocrinology; 2009; 90(3):235-44. PubMed ID: 19602868
[TBL] [Abstract][Full Text] [Related]
18. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.
Inoue T; Mizowaki T; Kabata D; Shintani A; Terada N; Yamasaki T; Negoro H; Kobayashi T; Nakamura K; Inokuchi H; Ogawa O
Clin Genitourin Cancer; 2018 Apr; 16(2):135-141.e1. PubMed ID: 29051056
[TBL] [Abstract][Full Text] [Related]
19. Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.
Niraula S; Templeton AJ; Vera-Badillo FE; Joshua AM; Sridhar SS; Cheung PW; Yip PM; Dodd A; Nugent Z; Tannock IF
Prostate; 2016 Feb; 76(2):235-42. PubMed ID: 26768279
[TBL] [Abstract][Full Text] [Related]
20. A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
Sayyid RK; Evans A; Hersey K; Maloni R; Hurtado-Coll A; Kulkarni G; Finelli A; Zlotta AR; Hamilton R; Gleave M; Fleshner NE
Clin Cancer Res; 2017 Apr; 23(8):1974-1980. PubMed ID: 27756786
[No Abstract] [Full Text] [Related]
[Next] [New Search]
